OverviewSuggest Edit

TearLab is an in-vitro diagnostic company, which develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. TearLab offers TearLab Osmolority System, which is intended to measure the osmolarity of human tears to aid in the diagnosis of dry eye disease in patients suspected of having dry eye disease, in conjunction with other methods of clinical evaluation.

TypePublic
Founded2003
HQSan Diego, US
Websitetearlab.com
Employee Ratings2.8

Latest Updates

Employees (est.) (Dec 2018)34(-12%)
Revenue (FY, 2018)$25 M(-7%)

Key People/Management at TearLab

Michael Berg

Michael Berg

Vice President of Regulatory
Sam Fakhoury

Sam Fakhoury

Vice President of Quality, Compliance and Supply Chain
Paul Smith

Paul Smith

Executive Vice President of Commercial Operations
Steve Zmina

Steve Zmina

Vice President of Manufacturing & Engineering
Show more

TearLab Office Locations

TearLab has an office in San Diego
San Diego, US (HQ)
9980 Huennekens St #100
Show all (1)

TearLab Financials and Metrics

TearLab Revenue

TearLab's revenue was reported to be $25 m in FY, 2018
USD

Revenue (Q2, 2019)

5.9m

Gross profit (Q2, 2019)

3.8m

Gross profit margin (Q2, 2019), %

65.1%

EBIT (Q2, 2019)

232.0k

Market capitalization (8-Oct-2018)

1.7m

Cash (30-Jun-2019)

9.2m

EV

27.3m
TearLab's current market capitalization is $1.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

14.6m19.7m25.2m28.0m27.1m25.0m

Revenue growth, %

35%28%11%

Cost of goods sold

8.1m8.8m10.8m10.2m11.0m

Gross profit

6.5m10.9m14.3m17.8m16.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

4.2m4.2m5.0m5.2m5.4m6.3m6.6m6.8m6.9m7.2m6.7m7.0m6.5m6.4m6.4m6.2m5.7m5.9m

Cost of goods sold

2.3m2.2m2.5m2.7m2.4m2.8m2.8m2.5m2.5m2.6m2.7m3.0m1.8m2.4m2.2m1.9m2.0m

Gross profit

1.9m2.0m2.5m2.5m3.0m3.5m3.8m4.2m4.4m4.7m4.3m3.5m4.6m4.1m4.0m3.8m3.8m

Gross profit Margin, %

46%48%51%48%56%56%57%62%64%65%62%54%72%63%65%66%65%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

37.8m16.3m13.8m15.5m7.3m8.5m

Accounts Receivable

3.5m2.5m3.0m2.3m1.5m1.2m

Inventories

885.0k4.0m3.2m2.0m2.0m

Current Assets

42.9m22.7m21.6m22.2m11.5m12.3m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

42.0m32.0m25.6m20.7m23.3m15.9m10.6m7.2m20.1m17.5m13.0m10.2m7.7m7.4m6.4m8.2m8.9m9.2m

Accounts Receivable

3.4m3.1m3.0m3.1m2.3m2.2m2.4m3.0m2.3m2.4m2.3m2.1m1.7m1.5m1.3m1.3m1.1m1.1m

Inventories

959.0k1.2m2.3m3.5m3.2m3.8m4.0m3.6m3.3m3.4m3.3m2.9m2.6m1.7m1.9m1.8m2.2m2.8m

Current Assets

46.8m36.9m31.4m28.1m29.8m22.7m17.9m15.1m26.8m24.2m19.8m16.3m12.7m11.2m9.9m11.7m12.8m13.5m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(33.2m)(19.9m)(16.1m)(2.3m)

Depreciation and Amortization

1.5m1.1m

Inventories

780.0k1.1m11.0k

Accounts Payable

(335.0k)(138.0k)(1.0m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(11.6m)(15.6m)(4.4m)(8.3m)(12.1m)(883.0k)(1.5m)(1.7m)(1.3m)(2.5m)

Depreciation and Amortization

395.0k382.0k382.0k382.0k382.0k304.0k382.0k359.0k

Inventories

2.3m3.5m3.2m3.8m4.0m338.0k665.0k568.0k(131.0k)313.0k603.0k314.0k143.0k245.0k(220.0k)(845.0k)

Accounts Payable

667.0k1.8m2.5m1.9m3.1m721.0k2.3m(328.0k)889.0k1.1m51.0k(647.0k)(1.3m)(666.0k)638.0k744.0k
USDY, 2019

EV/EBIT

117.7 x

EV/CFO

36.8 x

Financial Leverage

-0.7 x
Show all financial metrics

TearLab Online and Social Media Presence

Embed Graph

TearLab News and Updates

TearLab Corporation Reports Fourth Quarter and Full Year 2018 Financial Results

ESCONDIDO, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the fourth quarter and twelve months ended December 31, 2018. All dollar amounts are expressed in U.S. currency and results are …

TearLab Corporation Reports Third Quarter 2018 Financial Results

ESCONDIDO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”) today reported its consolidated financial results for the third quarter ended September 30, 2018. All dollar amounts are expressed in U.S. currency and results are reported in accord…

TearLab Update on 510(k) for U.S. FDA Clearance of Discovery™ MMP-9 Test

SAN DIEGO, Oct. 10, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB: TEAR) (“TearLab” or the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has determined that the TearLab Discovery™ MMP-9 test, has not met the criteria for substantial equivalence based upon data …

TearLab Frequently Asked Questions

  • When was TearLab founded?

    TearLab was founded in 2003.

  • Who are TearLab key executives?

    TearLab's key executives are Michael Berg, Sam Fakhoury and Paul Smith.

  • How many employees does TearLab have?

    TearLab has 34 employees.

  • What is TearLab revenue?

    Latest TearLab annual revenue is $25 m.

  • What is TearLab revenue per employee?

    Latest TearLab revenue per employee is $735.3 k.

  • Who are TearLab competitors?

    Competitors of TearLab include Atlantic Therapeutics, Crawford Healthcare and Non-Invasive Monitoring Systems.

  • Where is TearLab headquarters?

    TearLab headquarters is located at 9980 Huennekens St #100, San Diego.

  • Where are TearLab offices?

    TearLab has an office in San Diego.

  • How many offices does TearLab have?

    TearLab has 1 office.